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Objective We aimed to assess the health impact of a national control programme targeting schistosomiasis and intestinal nematodes 
in Uganda, which has provided population-based anthelmintic chemotherapy since 2003.
Methods We conducted longitudinal surveys on infection status, haemoglobin concentration and clinical morbidity in 1871 randomly 
selected schoolchildren from 37 schools in eight districts across Uganda at three time points — before chemotherapy and after one 
year and two years of annual mass chemotherapy.
Findings Mass treatment with praziquantel and albendazole led to a significant decrease in the intensity of Schistosoma mansoni 
— 70% (95% confidence interval (CI): 66–73%) after one year and 82% (95% CI: 80–85%) after two years of treatment. Intensity 
of hookworm infection also decreased (75% and 93%; unadjusted). There was a significant increase in haemoglobin concentration 
after one (0.135 g/dL (95% CI: 0.126–0.144)) and two years (0.303 g/dL (95% CI: 0.293–0.312)) of treatment, and a significant 
decrease in signs of early clinical morbidity. The impact of intervention on S. mansoni prevalence and intensity was similar to that 
predicted by mathematical models of the impact of chemotherapy on human schistosomiasis. Improvements in haemoglobin 
concentration were greatest among children who were anaemic or harbouring heavy S. mansoni infection at baseline.
Conclusion Anthelmintic treatment delivered as part of a national helminth control programme can decrease infection and 
morbidity among schoolchildren and improve haemoglobin concentration.
Bulletin of the World Health Organization 2007;85:91-99.
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Introduction
In Africa, schistosomiasis occurs predom-
inantly due to two species — Schistosoma 
haematobium that causes urinary schis-
tosomiasis and S. mansoni that causes 
intestinal schistosomiasis. Clinical trials 
have demonstrated that praziquantel is 
a safe and efficacious treatment against 
both species, and that repeated chemo-
therapy decreases infection and related 
morbidity.1–7 One of the main control 
methods is treating schoolchildren with 
praziquantel together with albendazole 
as part of school health programmes. 
As this method uses the existing school 
infrastructure and provides easy acces-
sibility to children, it is a cost-effective 
public health strategy,8 and many pilot 
programmes have demonstrated its 
feasibility, affordability and effective-
ness.9–13 It is unclear, however, whether 
the observed health benefits of such a 
control method can be replicated under 
nationwide programmatic conditions. 
Earlier large-scale helminth control 
efforts typically evaluated infection 
indicators, often prevalence, rather than 
morbidity indicators,14,15 but rarely con-
tinued due to financial problems and de-
creased effectiveness. Control of morbid-
ity related to schistosome infection has 
received new impetus with reduced drug 
prices,16 new approaches to control17,18 
and more recently, the establishment of 
the Schistosomiasis Control Initiative 
(SCI).19,20 We report the impact of re-
peated chemotherapy for schistosomiasis 
in Uganda — the first country to imple-
ment a control programme on a national 
scale — specifically, infection status, 
haemoglobin concentration and related 
clinical morbidity.
Methods
The national control programme
S. mansoni occurs throughout much of 
Uganda, with highest prevalence on the 
shores of the Albert Nile, Lake Albert 
and Lake Victoria.21 S. haematobium 
occurs only in a small focus and is 
of minor public health significance. 
Hookworm (predominantly Necator 
americanus) is prevalent throughout the 
country, whereas Ascaris lumbricoides 
and Trichuris trichiura are restricted to 
southwest Uganda.22 Uganda imple-
mented the SCI-supported control pro-
gramme in April 2003 with a pilot phase 
Research
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covering > 400 000 schoolchildren and 
community members (i.e. adults and 
school-aged children).23 Initially work-
ing in one sub-county in each of the 18 
most affected districts, the programme 
expanded to cover 0.53 million school-
children and 0.7 million community 
members in 23 districts in 2004, and 1.56 
million schoolchildren and 1.43 million 
community members in 2005. In schools, 
the programme provides mass treatment 
with praziquantel and albendazole to all 
children by schoolteachers. Community 
drug distributors provide treatment to 
all individuals above 94 cm in height 
within targeted communities. The annual 
mass treatment campaign is carried out 
between April and July every year.
Study design
We conducted three annual longitudinal 
surveys in a randomly selected sample 
of children aged 6–14 years from 37 
schools in eight districts following an-
nual mass treatment. The districts were 
selected to represent different transmis-
sion settings: Arua, Moyo and Nebbi, 
along the Albert Nile; Hoima and 
Masindi along Lake Albert; and Bugiri, 
Busia and Mayuge along Lake Victoria. 
Within each district, schools were strati-
fied according to S. mansoni infection 
prevalence: two with high prevalence 
(> 50%), two with medium prevalence 
(10–49%) and one with low prevalence 
(< 10%). In each school, 30 children (15 
males and 15 females) were randomly 
selected from four age groups: six, seven, 
eight and eleven years, yielding 120 
children. Twelve and 24 months later, we 
re-visited the schools and re-examined 
the same children if they could be traced. 
We undertook evaluation surveys every 
year during February–March in the 
Lake Victoria area, March–April in Lake 
Albert area, and October–November in 
the Albert Nile.
We obtained ethical clearance for 
our study from the Uganda National 
Council of Science and Technology 
and the Ethics Committee of Imperial 
College, London. We held meetings 
with the teachers and parents to explain 
the purpose of the study and obtained 
informed parental consent before com-
mencing the study. We also obtained 
assent from the children before samples 
were collected.
Procedures
We examined faecal samples from 
each child by the Kato-Katz method. 
Haemoglobin (Hb) concentration was 
estimated to an accuracy of 1 g/dL 
using a portable haemoglobinometer 
(Hemocue Ltd, Sheffield, England). 
Clinical examination consisted of liver 
and spleen palpation whilst children 
were in a supine position. We assessed 
liver and spleen changes by measuring 
the extensions below the rib cage along 
the right mid-clavicular line (MCL) and 
mid-sternal line (MSL) for the liver, and 
the extension below the rib cage along 
the left mid-clavicular and mid-axillary 
lines (MAL) for the spleen. The firmness 
of each palpable organ was recorded as 
normal, soft, firm or hard. Experienced 
technicians conducted ultrasound mea-
surements using a portable ultrasound 
machine (Aloca® Sonocamera SSD 
500) on children in Hoima and Mayuge 
districts only. We involved the same 
technicians in each survey to minimize 
inter-observer variation. We classified 
liver patterns on the basis of paren-
chymal fibrosis or other parenchymal 
pattern according to the World Heath 
Organization’s (WHO) protocol (Nia-
mey-Belo Horizonte).24 The following 
ultrasound measurements were made: the 
size of the left liver lobe was measured in 
the longitudinal parasternal line (PSL); 
portal vein diameters (PVD) were mea-
sured midway between the entrance of 
the portal hepatic and its bifurcation 
inside the liver. Following the WHO 
protocol, measurements of organ size 
and vein diameter were height-adjusted, 
using standard reference measurements 
for healthy members of the same popula-
tion group. We assumed that if the PSL 
height-adjusted value exceeded 2 or 4 
standard deviations (SD) in relation to 
the reference measurement the liver was 
considered enlarged or much enlarged. If 
the PVD height-adjusted value exceeded 
2 or 4 SD, it indicated portal vein dilata-
tion or marked dilatation.
Data analysis
We analysed the differences between 
dropouts and children successfully fol-
lowed up using the Kruskall-Wallis test 
for means and a c² test for proportions 
using SAS V8 (SAS Institute Inc., Cary, 
NC, USA).
We investigated the impact of treat-
ment on health outcomes using multi-
variate analysis. The analyses sought to 
overcome the presence of correlated data 
structures, whereby individual observa-
tions are nested within units and super-
units that make it likely that individual 
observations are not independent.25 In 
our study this involved children within 
schools and repeated measurements as 
data refer to baseline and two years of 
follow-up. To overcome this problem 
we performed a multi-level analysis 
that accounted for the interdependence 
of observations and partitioned the 
total variance into different compo-
nents of variation due to cluster levels 
in the data,26 using Mlwin (Multilevel 
Models Project, Institute of Education, 
London).
We used linear multi-level models 
to analyse changes in Hb levels among 
children in relation to their S. mansoni 
and/or hookworm infection intensity 
category (at follow-up there were very 
few children heavily infected with hook-
worm and therefore the convergence 
of the fitting algorithm in some of the 
models required pooling heavy and 
moderate hookworm intensities into 
one category), by adjusting for age, sex 
and anaemia status. Haemoglobin at 
baseline and every year following treat-
ment was modelled through 3-level 
models, where level-1 represented the 
three time points, level-2 the children 
and level-3 the schools. To take into 
account the longitudinal data structure, 
we included two dummy variables cor-
responding to the second and third 
years of the study as covariates in the 
model with the baseline as the reference 
category. Changes in Hb in relation 
to their baseline S. mansoni and/or 
hookworm infection intensity category 
and anaemia status from baseline to 
second year follow up were modelled 
through 2-level (children and schools) 
hierarchical models. Anaemia status was 
also included in the explanatory part of 
the model to examine increases in Hb 
in anaemic and non-anaemic subjects.27 
Models were fitted using maximum 
likelihood methods using “iterative gen-
eralized least squares”. Since the negative 
binomial distribution is a good empirical 
approximation of egg counts,28 we at-
tempted initially to fit a 3-level negative 
binomial model to evaluate factors that 
affected S. mansoni egg counts and to 
quantify changes over time. However, we 
encountered numerical problems during 
estimation and therefore fitted a 3-level 
“normal model” on the logarithmically 
transformed S. mansoni egg counts 
(ln(c+1)), using, due to its stochastic 
nature, a Markov chain Monte Carlo 
(MCMC) procedure.26
We performed Wald tests to ascer-
tain the statistical significance of the 
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fixed effects (i.e. those coefficients in the 
model which are treated as fixed values, 
such as age, sex). For the random effects, 
we performed likelihood ratio tests for 
the Hb models and the MCMC Devi-
ance Information Criterion for the egg 
counts models. All models presented are 
random intercept models with multiple 
independent variables.
Mathematical models of 
expected impact
Within programme districts, we could 
not implement the programme on 
a school-by-school basis. This was 
because, following discussions with 
national and district stakeholders, it 
was felt that having non-intervention 
schools would not bear relevance to the 
operational reality of a national control 
programme. Consequently, it was not 
possible to have a control population 
that did not receive treatment. We 
therefore compared observed epidemio-
logical changes in infection and disease 
and quantitative predictions arising 
from mathematical models,29,30 which 
predicted the impact of chemotherapy. 
The models, which were implemented 
using the EPISCHISTO software tool,31 
were successfully validated against data 
for S. mansoni in Kenya29 and can reli-
ably predict the impact of intervention 
using data aggregated by district.32 Pre-
intervention survey data on initial mean 
egg count, M, and estimated negative 
binomial aggregation parameter, k, were 
used as input data in the model predic-
tions. We assumed that all children aged 
5–15 years were treated and drug efficacy 
was 95%.2 The model predicts the mean 
egg count and prevalence of infection for 
children aged 5–16 years.
Findings
We enrolled 4351 children from 37 
schools, of which 2815 (64.7%) were 
traced and treated at one year follow-up 
and 1871 (43.0%) at two year follow-
up. The baseline characteristics did not 
differ significantly among those included 
in the evaluation one-year post treatment 
and those lost to follow-up (see Table 
1, available at http://www.who.int). 
However, we found the prevalence and 
mean intensity of S. mansoni to be sig-
Table 2. Health characteristics of Ugandan schoolchildren successfully followed up for two years (2003–05) and monitored as 
part of an evaluation of a national schistosomiasis control programme
2003 2004 2005
Parasitology (n = 1704)
% infected with Schistosoma mansoni  42.4  (40.0–44.7) a  26.8  (24.7–28.9)  17.9  (16.1–19.7)
% infected with hookworm  50.9  (48.6–53.3)  24.1  (22.1–26.2)  10.7  (9.3–12.2)
% infected with Ascaris lumbricoides  2.8  (2.0–3.6)  1.6  (1.0–2.3)  0.6  (0.3–1.0)
% infected with Trichuris trichiura  2.2  (1.5–2.9)  2.5  (1.7–3.2)  1.6  (1.0–2.2)
Mean S. mansoni intensity (epg)  219.6  (191.8–247.4)  73.3  (58.6–88.0)  37.4  (27.4–47.5)
Mean hookworm intensity (epg)  309.4  (232.4–386.3)  76.8  (62.9–90.7)  21.9  (13.7–30.1)
Haematology (n = 1852)
Mean haemoglobin (g/dL)  11.4  (11.3–11.5)  11.7  (11.6–11.7)  12.0  (11.9–12.1)
% anaemic  51.6  (49.3–53.8)  45.5  (43.3–47.8)  36.2  (34.0–38.4)
Ultrasound examination (n = 180)
% with liver grading B  39.4  (32.3–46.6)  9.4  (5.2–13.7)  1.7  (0.0–3.5)
% with PVD score 0: ‘normal’  82.2  (76.6–87.8)  98.0  (95.6–99.9)  96.7  (94.0–99.3)
% with PVD score 4: ‘dilatation’  17.8  (12.2–23.4)  2.2  (0.1–4.4)  3.3  (0.7–6.0)
% with PSL score 0: not enlarged  45.6  (38.3–52.8)  40.0  (32.8–47.2)  47.2  (39.9–54.5)
% with PSL score 1: enlarged  41.7  (34.5–48.9)  48.3  (41.0–55.6)  40.0  (32.8–47.2)
% with PSL score 2: much enlarged  12.8  (7.9–17.7)  11.7  (7.0–16.4)  12.8  (7.9–17.7)
Clinical examination (n = 368)
Liver
Median (range) in cm MSL  0.0  (0–12)  0.0  (0–14)  0.0  (0–14)
MCL  2.0  (0–5)  2.0  (0–5)  0.0  (0–6)
Consistency % normal  16.1  (12.4–19.9)  70.5  (65.8–75.2)  73.7  (69.3–78.3)
% soft  20.5  (16.4–24.6)  26.2  (21.7–30.7)  25.4  (20.9–29.9)
% firm  62.5  (57.6–67.5)  3.2  (1.5–5.1)  0.8  (0.0–1.7)
% hard  0.8  (0.0–1.7)  0.0  0.0
Tender  %  2.0  (0.5–3.4)  1.1  (0.0–2.2)  0.0
Spleen
Median (range) in cm MCL (n = 368)  3.0  (0–10)  0.0  (0–11)  0.0  (0–10)
MAL (n = 367)  0.0  (0–5)  0.0  (0–6)  0.0  (0–5)
Consistency % normal  26.1  (21.6–30.6)  63.3  (58.4–68.2) –
% soft  12.2  (8.9–15.6)  22.6  (18.3–26.8) –
% firm  58.4  (53.4–63.5)  14.1  (10.6–17.7) –
% hard  3.2  (1.5–5.1)  0.0
 epg, eggs per gram faeces; MAL, mid-axillary lines; MCL, mid-clavicular line; MSL, mid-sternal line; PVD, portal vein diameters; PSL, parasternal line.
a 95% confidence intervals in parentheses.
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nificantly higher among those children 
who were lost to follow-up compared to 
those successfully followed up two years 
post treatment.
Prevalence and intensity of 
infection
The health indicators of children 
surveyed (Table 2) showed that initial 
prevalence and intensity of S. mansoni 
infection (in 2003) among those fol-
lowed up for two years was 42.4% 
and 219.6 eggs per gram faeces (epg), 
respectively. In 2005, following two 
rounds of annual treatment, the preva-
lence and intensity of infection was 
17.9% and 37.4 epg, respectively. The 
function of negative binomial aggrega-
tion parameter to mean worm burden 
was estimated as k = 0.0278 + 0.0003. 
Overall, the mathematical model pre-
dicted the changes in the prevalence of 
infection and mean egg count within 
the confidence intervals of the observed 
data, indicating a close correspondence 
between the observed changes and the 
expected impact of intervention (Fig. 
1) Overall, the prevalence and inten-
sity of hookworm infections decreased 
from 50.9% and 309.4 epg to 10.7% 
and 37.4 epg (Table 2). At baseline, 
the prevalence of A. lumbricoides and T. 
trichiura was 2.8% and 2.2%, which de-
creased to 0.6% and 1.6%, respectively 
after two years.
The results of the multi-level “normal 
model” of the change in S. mansoni egg 
counts two years post treatment as well 
as differences in S. mansoni egg counts 
between different groups of children 
at baseline (Table 3) showed an overall 
significant decrease in the S. mansoni 
egg counts by 70% and 82%, one and 
two years post treatment, respectively 
(P < 0.001). At baseline, children aged 
six, seven and eight years had significant-
ly lower S. mansoni egg counts compared 
to those that were > 11 years old after 
adjusting for sex and anaemia status. 
Our analysis also showed that anaemic 
children at baseline had significantly 
15% more S. mansoni egg counts than 
non-anaemic children; the between-
school variation in S. mansoni egg counts 
was wider than that of between children 
within schools.
Haemoglobin concentration
A significant increase in haemoglobin 
(Hb) (11.4 to 12.0 g/dL) and a signifi-
cant decrease in the prevalence of anae-
mia (51.6 to 36.2%) were observed from 
Fig. 1. Comparisons of observed changes in (a) prevalence of Schistosoma mansoni 
infection and (b) intensity of S. mansoni infection as part of a national 
schistosomiasis control programme in Uganda, 2003–05
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2003 to 2005 (Table 2). The 3-level lin-
ear multi-level model of changes in Hb 
concentration suggests that there was an 
overall significant increase of 0.135 g/dL 
in Hb concentration after one treatment 
and of 0.303 g/dL after two treatments 
(Table 4). Our analysis also showed 
that children moderately infected with 
S. mansoni had significantly lower Hb 
(–0.169 g/dL) compared to uninfected 
a epg, eggs per gram faeces
Figures show expected changes based on predictions arising from a deterministic mathematical model of 
the expected impact of school-based chemotherapy.
Diamonds show the observed values and solid lines show the model prediction. Errors bars indicate 95% 
confidence intervals.
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Table 3. Estimates from 3-level normal hierarchical model for log transformed 
Schistosoma mansoni egg counts before and after treatment among 1682 
Ugandan schoolchildren, 2003–05
Parameter Coefficient (95% CIs) P values
Sexa
Female g01  -11%  (-21% to 0%) 0.049
Age at baselineb
9 years old g02  -6.5%  (-20% to 9%) 0.387
8 years old g03  -21%  (-31% to -9%) < 0.001
7 years old g04  -31%  (-42% to -18%) < 0.001
6 years old g05  -62%  (-70% to -50%) < 0.001
Effect of follow-up (relative to 
baseline)
Follow-up year 1 g06  -70%  (-73% to -66%) < 0.001
Follow-up year 2 g07  -82%  (-85% to -80%) < 0.001
Anaemia status at baselinec
Anaemic g08  15%  (4% to 28%) 0.008
Random effectsd Variance components (SE)
Level-3 (between schools) variance
s²v = Var (v0k ) 0.468 (0.123) 
Level-2 (between children within a 
school) variance
s²u = Var (u0jk ) 0.100 (0.011)
Level-1 (measurement occasions 
within a child) variance
s²e = Var (e0ijk ) 0.516 (0.013)
Deviance 10980.13
CI, confidence interval; SE, standard error. 
a  Reference category: male.
b  Reference category: > 11 years old.
c  Reference category non-anaemic children.
d  Random effects variance components refer to log Schistosoma mansoni egg counts.
children at baseline, while heavily in-
fected children had significantly further 
lower Hb (–0.328 g/dL). Children with 
moderate or heavy hookworm infection 
at baseline had significantly lower Hb 
(–0.493 g/dL) than those uninfected 
after adjusting for S. mansoni intensity, 
age, sex and anaemia status. We found 
that while the random effects variance 
components indicated much of the 
variance being between children within 
a school, there was also statistically sig-
nificant variance between schools. Of the 
total variability in Hb, 31.6% occurred 
between children within a school and 
5.6% occurred across schools.
The 2-level linear multilevel model 
of changes in Hb during 2003–05 indi-
cated that this change varied significantly 
only as a function of baseline heavy S. 
mansoni infection and baseline anaemia 
status (Table 5). For children heavily 
infected with S. mansoni at baseline, 
Hb increased by 0.25 g/dL compared 
to those uninfected with S. mansoni 
at baseline. Additionally, for anaemic 
children compared to the non-anaemic 
Hb increased by 1.20 g/dL.
Clinical and ultrasound 
measurements
We had complete longitudinal clinical 
examination data for 368 children, aged 
6–13 years and complete longitudinal 
ultrasound data for 180 children, aged 
8–13 years. The percentage of children 
with a firm liver significantly decreased 
from 62.5% in 2003 to 3.2% in 2004 
and 0.8% in 2005 (Table 2). While 
three (0.8%) children had a hard liver 
in 2003, by 2004 none had a hard liver. 
The prevalence of hardened spleens 
decreased from 3.2% in 2003 to none 
in 2004; the prevalence of firm spleens 
also significantly decreased over time. 
At baseline, 39.4% of children had 
liver pattern B (early suggestive changes) 
that significantly decreased to 9.4% in 
2004 and 1.7% in 2005 (Table 2). No 
schoolchild had patterns C to F (indica-
tive of fibrosis). We recorded a dilated 
portal vein in 17.8% children in 2003, 
2.2% in 2004 and 3.3% in 2005. No 
schoolchild had marked dilation in any 
of the surveys.
Discussion
Our results showed that praziquantel 
and albendazole can have a significant 
impact on infection and associated 
morbidity when delivered as part of a 
large-scale control programme. Mass 
treatment led to a decrease in the 
prevalence and intensity of S. mansoni 
and hookworm infections, a significant 
increase in Hb and a decrease in clinical 
morbidity. Children who were anaemic 
or harbouring  heavy S. mansoni infec-
tion at baseline recorded the maximum 
increase in Hb concentration.
Limitations and plausibility
Cluster-randomized trials are the ac-
cepted gold standard for the evaluation 
of health interventions delivered at the 
community level.33,34 However, we could 
not study control cohorts of children 
because a randomized controlled design, 
i.e. a probability design,35 probably 
would not bear relevance to the opera-
tional reality of the national programme 
and would be politically difficult to 
implement and ethically inappropri-
ate.14 Therefore, chance and bias could 
perhaps contribute to the differences 
observed compared to randomized con-
trolled trials. Potential biases included 
the influence of unobserved potential 
confounders, many which are difficult to 
measure such as duration of residence.36 
An important unmeasured confounder 
could be secular changes in the expo-
sure to, as well as potential treatment 
of, malaria infections, which influence 
both Hb and splenomegaly.5 However, 
our study presented plausible evidence 
of the impact of the intervention since 
we observed significant changes in infec-
tion and morbidity in randomly sampled 
children in 37 schools across different 
transmission settings in the country, 
after adjusting estimates for age and sex 
differences and potentially confounding 
variables. Additionally, there was a close 
agreement between the observed impact 
and mathematical model predictions 
of programme effectiveness. Thus, our 
analyses provided further validation of 
the models and showed that the ob-
served impact is similar to that expected 
on the basis of the known population 
dynamics of infection and disease as well 
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as the well-established therapeutic effi-
cacy and health benefits of praziquantel 
and albendazole.29,37 That our observed 
changes were indeed actual and signifi-
cant is further strengthened by two key 
observations — first, both the intensity 
of infection and the rates of anaemia and 
clinical morbidity decreased after drug 
treatment; and second, our multi-level 
analysis indicated that the increase in 
Hb was highest among children who 
harboured heavy S. mansoni infection at 
baseline. We believe that as countrywide 
delivery of interventions with known 
health benefits are progressively being 
implemented, it may be increasingly 
difficult to include control groups in 
programme evaluation. Such a situation 
inevitably however, lessens the plausibil-
ity of any statement attributing a health 
impact of the intervention. Clearly there 
is a trade-off between what is scien-
tifically desirable and what is politically 
realistic.
Impact on anaemia
Our evaluation provided evidence that 
the programme increased Hb in school-
children. Among school-aged children 
living in sub-Saharan Africa, several 
parasites contribute to anaemia — while 
predominately due to hookworm infec-
tion, it may be caused by schistosome 
and Plasmodium falciparum infec-
tion.38– 41 Hookworm and schistosomes 
cause iron deficiency anaemia due to 
intestinal blood loss 38,39 or chronic in-
fection anemia due to chronic immune 
activation or inflammatory cytokine 
disturbances. Though malaria decreases 
Hb concentration through a number 
of mechanisms, it occurs principally 
by the destruction of parasitized and 
non-parasitized red cells and dyseryth-
ropoiesis.41 Most studies in school-aged 
children have typically found that 
hookworm contributes more to anae-
mia than schistosomiasis or malaria 42,43 
and we suggest that the increase in Hb 
in our study is most likely related to the 
decrease in the prevalence and intensity 
of either hookworm or both hookworm 
and schistosome infections. Since both 
praziquantel and albendazole were 
delivered as part of the same health 
package we could not separate the 
relative contribution of either drug to 
the observed increase in Hb. However, 
recent experience of a school health 
programme in Tanzania demonstrated 
that deworming with albendazole and 
praziquantel decreased the prevalence 
Table 4. Estimates from 3-level hierarchical model for haemoglobin concentration 
before and after treatment among 1789 Ugandan schoolchildren, 2003–05
Parameter Coefficient (SE) P values
Intercept g00  11.814  (0.084) < 0.001
Intensity of Schistosoma mansoni 
infection at baselinea 
Light g01  -0.081  (0.051) 0.113
Moderate g02  -0.169  (0.068) 0.013
Heavy g03  -0.328  (0.075) < 0.001
Intensity of hookworm infection at 
baselinea
Light g04  0.014  (0.040) 0.117
Moderate/Heavy g05  -0.493  (0.157) 0.002
Sexb 
Female g06  0.066  (0.045) 0.144
Age at baselined
9 years old g07  -0.209  (0.051) < 0.001
8 years old g08  -0.316  (0.048) < 0.001
7 years old g09  -0.563  (0.062) < 0.001
6 years old g10  -0.608  (0.082) < 0.001
Effect of follow-up (relative to 
baseline)
Follow-up year 1 g11  0.135  (0.044) 0.002
Follow-up year 2 g12  0.303  (0.051) < 0.001
Random effects Variance componentse (SE)
Level-3 (between schools) variance
s²v = Var (v0k ) 0.097 (0.028)
Level-2 (between children within a 
school) variance
s²u = Var (u0jk ) 0.539 (0.031)
Level-1 (measurement occasions 
within a child) variance
s²e = Var (e0ijk ) 1.069 (0.025)
Deviance 17314.6
SE, standard error.
a  Reference category: uninfected.
b  Reference category: male.
c  Reference category: > 11 years old. 
d  The total variance is 1.705, the sum of the three variance components [Var(v0k), Var(u0jk) and 
Var(e0ijk)]. Of the total variance, 0.097/1.705=5.6 percent is situated at the school level while 
0.539/1.705=31.61% is situated at the children level.
of anaemia and moderate-severe anae-
mia by 26% and 47%, respectively, 
15 months after treatment.12
Clinical morbidity
We did not observe periportal fibrosis 
among schoolchildren, which was not 
surprising since studies indicated a time 
lag of 5–10 years between peak inten-
sity of infection and the occurrence of 
fibrosis, with greatest prevalence among 
adults.7,36 However, 39.4% of children 
had liver pattern B, indicative of early 
signs of morbidity. Following treat-
ment, the prevalence of liver pattern B 
decreased significantly. These findings 
are in accordance with previous studies 
among schoolchildren which showed 
marked reversal in periportal fibrosis,6,44 
and marked and prolonged decrease 
in the prevalence of splenomegaly and 
hepatomegaly.45,46 These reports together 
with our findings suggests that limiting 
the effects of infection at an early age 
can decrease early disease and possibly 
prevent permanent liver damage. Given 
our study design, however, other con-
founding factors, such as malaria and 
chronic hepatitis B, cannot be com-
pletely excluded.
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Conclusions
We found that large-scale implementa-
tion of anthelmintics delivered through 
the school system can significantly de-
crease infection and morbidity among 
Ugandan schoolchildren. The experi-
ence of the Uganda national control 
programmes confirms that the potential 
of helminth control, previously demon-
strated through pilot programmes,8,12,13 
can be realized at realistic geographical 
scale in sub-Saharan Africa. However, a 
key challenge for national control pro-
grammes outside sub-Saharan Africa 
has been to sustain initial morbidity 
gains over time.47, 48 We conclude that 
the major challenge for the Ugandan 
programme would be to ensure regular, 
continued and sustainable large-scale 
delivery of anthelmintics to achieve and 
maintain long lasting health benefits.  O
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Table 5.  Estimates from 2-level hierarchical model for the change in haemoglobin 
concentration among 1789 Ugandan schoolchildren, 2003-05
Parameter Coefficient (SE)  P values
Intercept g00  0.027  (0.107) 0.800
Intensity of Schistosoma mansoni 
infection at baselinea 
Light g01  -0.072  (0.092) 0.436
Moderate g02  -0.032  (0.111) 0.774
Heavy g03  0.250  (0.108) 0.020
Intensity of hookworm infection at 
baselinea
Light g04  -0.009  (0.066) 0.896
Moderate/Heavy g05  0.245  (0.201) 0.223
Sexb 
Female g06  -0.021  (0.062) 0.734
Age at baselinec
9 years old g07  0.014  (0.087) 0.875
8 years old g08  -0.012  (0.088) 0.891
7 years old g09  -0.106  (0.090) 0.240
6 years old g10  0.027  (0.107) 0.800
Anaemia status at baselined
Anaemic g11  1.204  (0.064) <0.001
Random effects Variance components (SE)
Level-2 (between schools) variance
s²u = Var (u0jk ) 0.105 (0.034)
Level-1 (between children within a 
school) variance
s²e = Var (e0ijk ) 1.675 (0.057)
Deviance 6051.5
SE, standard error.
a  Reference category: uninfected.
b  Reference category: male.
c  Reference category: > 11 years old. 
d  Reference category: non-anaemic children.
Résumé
Impact d’un programme national de lutte contre les helminthes sur les taux d’infestation et de 
morbidité dues à ces parasites chez des écoliers ougandais
Objectif Nous nous sommes efforcés d’évaluer l’impact sur la 
santé d’un programme national de lutte contre la schistosomiase 
et contre les nématodes intestinaux en Ouganda, qui dispense une 
chimiothérapie antihelminthique en population depuis 2003.
Méthodes Nous avons réalisé une enquête longitudinale sur le 
statut infectieux, le taux d’hémoglobine et la morbidité clinique 
chez 1871 écoliers, choisis au hasard parmi 37 écoles relevant 
de 8 districts, répartis à travers l’Ouganda, en mesurant ces 
paramètres à trois moments différents : avant chimiothérapie, un 
an après une chimiothérapie massive annuelle et deux ans après 
ce traitement.
Résultats Le traitement massif par le praziquantel et l’albendazole 
a entraîné une diminution importante de l’intensité de l’infestation 
par Schistosoma Mansoni : 70 % [intervalle de confiance à 95 % 
(IC) = 66 – 73 %] après un an et 82 % [intervalle de confiance à 
95 % (IC) = 80 – 85 %] après deux ans de traitement. L’intensité 
de l’infestation par les ankylostomes a aussi baissé [de 75 % et 
de 93 % respectivement (valeurs non ajustées)]. On a relevé une 
hausse importante du taux d’hémoglobine après un an [0,135 
g/dl (IC à 95 % = 0,126 – 0,144)] et deux ans [0,303 g/dl 
(IC à 95 % = 0,293 – 0,312)] de traitement et une diminution 
notable des signes précoces de morbidité clinique. L’impact de 
l’intervention sur les concentrations de S. mansoni a été similaire 
à celui prévu par des modèles de l’impact de la chimiothérapie sur 
la schistosomiase humaine. C’est chez les enfants anémiques ou 
fortement infestés par S. mansoni au départ que l’on a relevé les 
plus fortes améliorations du taux d’hémoglobine.
Conclusion Le traitement antihelminthique délivré dans le cadre 
d’un programme national de lutte contre les helminthes est en 
mesure de faire baisser les taux d’infestation et de morbidité chez 
les écoliers et d’améliorer leur taux d’hémoglobine.
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Resumen
Impacto de un programa nacional de lucha antihelmíntica en la intensidad de la infección y la morbilidad 
entre escolares de Uganda
Objetivo Decidimos evaluar el impacto sanitario de un programa 
nacional de control centrado en la esquistosomiasis y las 
infecciones intestinales por nematodos en Uganda, país que viene 
proporcionando tratamiento antihelmíntico a nivel poblacional 
desde 2003. 
Métodos Realizamos estudios longitudinales sobre la intensidad 
de la infección, la concentración de hemoglobina y la morbilidad 
clínica en 1871 escolares seleccionados al azar en 37 escuelas 
de ocho distritos de Uganda en tres momentos: antes del 
tratamiento, y al cabo de uno y dos años de la antibioticoterapia 
masiva anual.
Resultados El tratamiento masivo con prazicuantel y albendazol 
se tradujo en una importante disminución de la intensidad de la 
infección por Schistosoma mansoni: 70% (intervalo de confianza 
(IC) del 95%: 66%–73%) al cabo de un año, y 82% (IC95%: 
80%–85%) a los dos años de tratamiento. La intensidad de 
la anquilostomiasis también disminuyó (75% y 93%; cifras no 
ajustadas). Se produjo un aumento considerable de la concentración 
de hemoglobina al cabo de un año (0,135 g/dl (IC95%: 
0,126–0,144)) y a los dos años (0,303 g/dl (IC95%: 0,293–0,312)) 
de tratamiento, así como una disminución significativa de los 
signos de morbilidad clínica precoz. El impacto de la intervención 
en la prevalencia y la intensidad de la infección por S. mansoni 
fue similar al proyectado por los modelos matemáticos del 
impacto de la antibioticoterapia en la esquistosomiasis humana. 
La concentración de hemoglobina mejoró sobre todo entre los 
niños que estaban anémicos o que presentaban signos serios de 
infección por S. mansoni al comienzo del estudio.
Conclusión El tratamiento antihelmíntico suministrado en el 
marco de un programa nacional de control de helmintos permite 
reducir la intensidad de la infección y la morbilidad entre los 
escolares y mejorar la concentración de hemoglobina.
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صخلم
ادنغوأ في سرادلما ذيملات ىدل ةضارلماو ىودعلا لىع ةيليفطلا ناديدلا ةحفاكلم ينطو جمانرب يرثأت
 ةحفاكلم ينطو جمانبرل يحصلا رثلأا ميـيقت ةساردلا هذه تفدهتسا :فدهلا
 اذه  م َّدق  ثيح  ،ادنغوأ  في  ةيوعلما  ةدوسملما  ناديدلاو  تايسراهلبلا  ءاد
.2003 ماع ذنم ناكسلل ناديدلل ةدراط ةيئايميك ةجلاعم جمانبرلا
 عضو  ةفرعلم  ةيلوط  تاحوسم  ةساردلا  هذه  راطإ  في  انيرجأ  :ةقيرطلا
 ذيملات  نم  1871  ىدل  ةيريسرلا  ةضارلماو  ،ينبولغوميهلا  زيكرتو  ،ىودعلا
 ادنغوأ في قطانم نياثم في ةسردم 37 نم ًايئاوشع مهؤاقتنا مت نيذلا سرادلما
 ةجلاعلما نم ةنس دعبو ،ةيئايميكلا ةجلاعلما لبق :ةفلتخم تاقوأ ةثلاث فيو
.ةجلاعلما هذه نم ينتنس دعبو ،ةيونسلا ةيعومجلا ةيئايميكلا
 ضفخ لىإ لوزادنيبلاو ليتناوكيزابرلاب ةيعومجلا ةجلاعلما تدأ :تادوجولما
 %70  هرادقم  ًاضافخنا  تققح  ذإ  ،ةينوسنلما  ةيسراهلبلا  ةفاثك  في  يربك
 دعب  )%73  لىإ  66  نم  ضافخنلاا  حوارت  ثيح  %95  ةقثلا  ةلصاف  دنع(
 ثيح ،%95 ةقثلا ةلصاف دنع( %82 هرادقم ًاضافخناو ،ةجلاعلما نم ةنس
 تضفخناو  .ةجلاعلما  نم  ينتنس  دعب  )%85  لىإ  80  نم  ضافخنلاا  حوارت
 ةنس  دعب  %75  ةبسنب  )اموتسلكنلأا(  ةي ِّص ِّشلا  ةدودلاب  ىودعلا  ةدش  ًاضيأ
 ًايئاصحإ  ةمهم  ةدايز  تظحولو  .)ةح َّحصم  يرغ(  ينتنس  دعب  %93  ةبسنبو
 )ترل سييد/غ 0.135 اهرادقم( ةجلاعلما نم ةنس دعب ينبولغوميهلا زيكرت في
 دعبو ،)0.144  لىإ   0.126   نم تحوارت  ثيح :%95  ةقثلا  ةلصاف دنع(
 :%95 ةقثلا ةلصاف دنع( )ترل سييد/غ 0.303 اهرادقم( ةجلاعلما نم ينتنس
 في ًايئاصحإ مهم ضافخنا ظحول ماك ،)0.312 لىإ 0.293  نم تحوارت ثيح
 لخدتلا رثأ نأ ةساردلا تنَّيبو .ةركبلما ةيريسرلا ةضارلما لىع ةلادلا تاملاعلا
 ةجلاعلما  يرثأتل  لثمام  هتدشو  ةينوسنلما  ةيسراهلبلا  راشتنا  لىع  يجلاعلا
 ناكو .ةيضايرلا  جذمانلا  تاعقوتل  ًاقفو ،ةيشربلا  ةيسراهلبلا  لىع ةيئايميكلا
 رقفب  ينباصلما  لافطلأا  ىدل  نوكي  ام  لىعأ  ينبولغوميهلا  زيكرت  في نسحتلا
.ساسلأا في ةينوسنلما ةيسراهلبلاب ةديدش ىودعب ينباصلما وأ مدلا
 ينطو  جمانرب  راطإ  في  ةمدقلما  ،ناديدلل  ةدراطلا  ةجلاعلما  نإ  :جاتنتسلاا
 ،سرادلما  ذيملات  ينب  ةضارلماو  ىودعلا  نم  دحت  ةيليفطلا  ناديدلا  ةحفاكلم
.مدلا ينبولغوميه زيكرت ن ِّسحتو
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Table 1. Baseline characteristics of Uganda schoolchildren followed up for one year and not followed up, and of children 
followed up for two years (2003–05) and not followed up
Followed for 
one year
Not followed 
up
P value Followed for 
two years
Not followed 
up
P value
Mean (range) age 8.1
(n = 2815)
8.1
(n = 1536)
0.615 8.0
(n = 1871)
8.1
(n = 2480)
0.216
% male 51.0
(n = 2004)
50.2
(n = 705)
0.726 55.1
(n = 1867)
50.5
(n = 844)
0.804
% infected with S. mansoni 44.3
(n = 2719)
46.7
(n = 1470)
0.135 42.0
(n = 1806)
47.5
(n = 2383)
< 0.001
% infected with hookworm 51.8
(n = 2718)
51.4
(n = 1470)
0.771 51.0
(n = 1806)
52.2
(n = 2382)
0.454
Mean (SD) Schistosoma mansoni 
intensity (epg)
245.1
(619.6)
322.8
(809.7)
0.056 217.3
(579.3)
314.1
(765.7)
< 0.001
Mean (SD) hookworm intensity (epg) 277.5
(917.9)
299.9
(1367.9)
0.944 302.9
(1577.18)
283.8
(877.3)
0.169
% anaemica 49.9
(n = 2785)
49.2
(n = 1486)
0.630 51.5
(n = 1857)
48.3
(n = 2414)
0.140
Mean (SD) haemoglobin (g/dL) 11.4
(1.4)
11.4
(1.4)
0.872 11.4
(1. 4)
11.4
(1.4)
0.184
% with liver grading ‘B’ 38.6
(n = 298)
29.7
(n = 263)
0.083 39.4
(n = 180)
32.02
(n = 381)
0.022
% with abnormal PVD score 15.8
(n = 298)
16.73
(n = 263)
0.759 17.8
(n = 180)
15.5
(n = 381)
0.492
% with abnormal PSL score 57.1
(n = 298)
59.7
(n = 263)
0.526 54.5
(n = 180)
60.1
(n = 381)
0.204
% with abnormal liver consistency 83.4
(n = 375)
80.09
(n = 523)
0.194 83.9
(n = 368)
79.85
(n = 660)
0.113
% with abnormal spleen consistency 73.8
(n = 367)
74.6
(n = 650)
0.824 NA NA NA
epg, eggs per gram faeces; SD,standard deviation; NA, Data not collected; PSL, parasternal line; PVD, portal vein diameters.
a Anaemia was defined for all tables displayed (according to WHO guidelines), as Hb less than 11.5 g/dL for children from 5 to 11 years old and for children 
between 12 and 14 years old  as Hb less than 12.0 g/dL.
